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Abstract
Background
Use of a reduced intensity conditioning regimen before an allogeneic hematopoietic cell transplantation is frequently associated with
an early state of mixed hematopoietic chimerism. Such a co-existence of both host and donor hematopoietic cells may influence
post-transplant alloreactivity and may affect the occurrence and severity of acute and chronic graft-versus-host disease (GVHD) as
well as the intensity of the graft-versus-leukemia effect. Here we evaluated the relation between chimerism state after reduced
intensity conditioning transplantation (RICT), auto-antibody production and chronic GVHD (cGVHD)-related pathology.
Methods
Chimerism state, circulating anti-cardiolipin and anti-double stranded DNA auto-antibody (Ab) titers as well as occurrence of
cGVHD-like lesions were investigated in a murine RICT model.
Results
We observed a novel association between mixed chimerism state, high levels of pathogenic IgG auto-Abs and subsequent development
of cGVHD-like lesions. Furthermore, we found that the persistence of host B cells, but not dendritic cell origin or subset, was a factor
associated with the appearance of cGVHD-like lesions. The implication of host B cells was confirmed by a host origin of auto-Abs.
Conclusions
Recipient B cell persistence may therefore contribute to the frequency and/or severity of cGVHD after RICT.
MESH Keywords Animals ; Autoantibodies ; blood ; Autoimmunity ; Bone Marrow Transplantation ; immunology ; pathology ; Hematopoietic Stem Cells ; physiology ; 
Immunoglobulin G ; blood ; Immunoglobulin M ; blood ; Interferon-gamma ; blood ; Interleukin-13 ; blood ; Mice ; Mice, Inbred BALB C ; Transplantation Chimera ; 
immunology
Author Keywords chimerism ; GVHD ; autoimmunity ; B cells
INTRODUCTION
The recent introduction of reduced intensity conditioning (RIC) regimens has modified allogeneic hematopoietic cell (HC)
transplantation. While shifting away from toxic myeloablative conditioning regimens, such an approach can result in increased graft failure
( ). In addition, reduced intensity conditioning transplantation (RICT) might be associated with less frequent incidence, less severe1 
clinical form and/or delayed onset of acute graft-versus-host disease (GVHD) than conventional myeloablative allograft while a similar
frequency of chronic graft-versus-host disease (cGVHD) has been reported ( ). Allogeneic RICT are associated with delayed1 –4 
conversion to full-donor chimerism with longer host HC persistence. In experimental murine models, this state of mixed chimerism
observed after allogeneic RICT offers several advantages over full-donor chimerism, including immunological competence ( ), reciprocal5 
graft-host tolerance ( , ) and superior graft-versus-leukemia (GvL) effect ( ). All these advantages have been related to the presence of5 6 7 
both recipient and donor antigen-presenting cells (APC) ( ). Dendritic cells (DC) can be considered as the major APC involved in the5 –7 
control of allo-immune responses after BMT (as discussed in Ref. ). Donor DC homing in the thymus may participate to negative8 
selection of alloreactive T cells together with host DC. In peripheral organs, host APC and notably DC seems to be critical to initiate acute
GVHD ( , ) and to favor GvL effect ( ). However, other immunologically active host HC subsets than DC persist and may9 10 7 – –
influence the alloreactive interactions between donor and host immune cells. Here, we observed in a murine bone marrow transplantation
(BMT) model that mixed chimeric mice presented higher levels of circulating pathogenic IgG auto-antibodies (Abs) than in non- or
full-donor chimeric mice and preferentially developed cGVHD-like lesions. This increase of IgG auto-Abs in mixed chimeric mice was
associated with an increase of total IgG levels. This suggests a polyclonal activation in these mixed chimeric recipients that can be related
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to the alloreactive conflict observed after transplantation. The persistence of host B cells together with donor T cells was identified as a
factor associated with cGVHD occurrence. The involvement of host B cells in mixed chimeric mice was confirmed by the recipient origin
of circulating auto-Abs. Such observation might be clinically relevant and contribute to cGVHD occurrence and/or severity after
allogeneic RICT.
MATERIALS AND METHODS
Bone marrow transplantation
Pathogen-free male (5 6 weeks) BALB/c mice (Janvier, Le Genest-St-Isle, France) received a limited number of bone marrow (BM)–
cells (10 ) from FVB donors following a sub-lethal 6 Gy total body irradiation. Experiments were performed according to institutional6 
guidelines. All mice described in this study corresponded initially to control recipients used to evaluate novel cell-based therapy
approaches favoring HC engraftment. The initial observation consisting of a retrospective analysis involving six independent experiments–
 was done by chance when some of these control receiving only a limited number of BM cells developed late GVHD-like lesions (> 45–
days). These lesions were identical to those encountered in the chronic form of GVHD, as attested by pathological examination. Then,
three prospective experiments were performed to further explore cellular factors involved in the occurrence of cGVHD in mixed chimeric
mice.
Chimerism analysis
Engraftment was evaluated on either splenocytes or thymocytes at time of sacrifice or on peripheral blood mononuclear cells (kinetic
studies) by flow cytometry using specific anti-H2 monoclonal Abs (mAbs), as previously reported ( ). Recipients were considered11 
full-donor chimeric when > 98  of cells exhibited donor phenotype, non-chimeric in the absence (< 2 ) of donor cells, and mixed in all% %
other cases. In some additional experiments (prospective studies), allophycocyanin-conjugated anti-CD3 (145-2C11), -CD8 (53-6.7),
-CD45 (30-F11), -H2 (KH117), FITC-conjugated anti-CD44 (IM7), -H2 (KH117), -B220 (RA3-6B2), -IgM (R6-60.2), phycoerythrinq q 
(PE)-conjugated anti-CD3 (145-2C11), -CD5 (53-7.3), -CD11c (HL3), -CD19 (1D3), -H2 (SF1-1.1), -CD62L (MEL-14), peridinind 
chlorophyll-a protein (PerCP)-conjugated anti-CD4 (RM4-5), -B220 (RA3-6B2), PerCP-cyanin 5.5-conjugated CD11b (M1/70) (BD
Biosciences PharMingen, Le Pont de Claix, France) and PE-cyanin 5-conjugated anti-F4/80 (A3-1, Serotec, Oxford, UK) mAbs were used
to evaluate engraftment in T, B, and DC subsets. Absolute counts of circulating leukocyte subsets were determined using a single-platform
approach based on cytometry and tubes containing a defined number of microbeads (TruCOUNT , BD Biosciences) ( ). In this lyse no® 12 “
wash  method, side scatter (SSC) vs. CD45 fluorescence gating permits the discrimination of leukocytes from nucleated erythroid cells and”
debris ( ). The kinetics of engraftment in this BMT model was determined by sequential sacrifices of grafted mice. Donor cells with a12 
myeloid morphology (forward scatter FSC /SSC gating) first appeared in the BM 2 days after BMT. At day 8 post-BMT, donor cells[ ]
disappeared in the BM of non-engrafted mice while persisted in the marrow of engrafted mice. Donor cells with both lymphoid and
myeloid morphology were detected only after day 6 8 in other sites including the spleen and blood of engrafted mice. The only exception–
was donor T cells likely to persist and circulate in non-engrafted mice until sufficient autologous immuno-hematological reconstitution
occurred.
Auto-antibody detection
Anti-double stranded (ds) DNA and anti-cardiolipin (AcL) auto-Abs were assessed by ELISA, as described ( ). Briefly, Maxisorp13  ™
immunoplates (Nunc, Naperville, IL) were coated overnight at 4 C with 10 g/mL of calf thymus DNA (Sigma, Saint Quentin Fallavier,° μ
France) in borate buffered saline. The plates were washed with phosphate buffer saline (PBS) and then saturated with a blocking buffer
containing 0.5  fetal calf serum (FCS, Boehringer Mannheim, Meylan, France) and 0.2  of sodium azide (Sigma) in PBS. Different% %
dilutions of serum were added and incubated for 2 hours. Immune complexes (IC) were detected with biotinylated goat anti-mouse IgG or
IgM (Jackson ImmunoResearch Laboratories, West Grove, PA) followed by Horseradish Peroxidase conjugated Streptavidin (BD
Biosciences PharMingen). Then a solution of TMB substrate (3,3 ,5,5 -tetramethylbenzidine, Moss Inc, Pasadena, MD) was added. The′ ′
presence of anti-dsDNA Abs was determined by measuring optical density at 620 nm. For the detection of AcL auto-Abs, Polysorp  ™
immunoplates (Nunc) were coated overnight with 50 g/mL of cardiolipin (Sigma) in ethanol. After saturation of the plates with a 10μ %
FCS PBS solution, different dilutions of serum were added and incubated for 3 hours. Revelation of AcL auto-Abs (IgG and IgM) was
performed as described for anti-dsDNA Abs. Normal mouse serum (Sigma) was used to obtain a standard curve for natural IgM Ab titer
determination. Serum from autoimmune-prone MRL mice (provided by Luc Reininger, Marseille, France) was used as positivelpr/lpr 
control for IgG auto-Ab detection and to obtain a standard curve for IgG Ab titer determination. Experimental values from separate
experiments were normalized to a single MRL- positive control serum used in every assay. The origin of auto-Abs can belpr/lpr- 
determine since the mouse strains used differ at the locus: BALB/c mice carry the a  allotype ( gene haplotype), while C57BL/cIgh “ ” Igh-Ca 
mice carry the haplotype (b allotype) and FVB mice carry neither the nor haplotype (non a non b allotype).Igh-Cb Igh-Ca Igh-Cb 
Allotype-specific ELISA ( ) were performed using rabbit anti-mouse 1a allotype or anti-1b allotype anti-serum (Nordic Immunology,14 
Tilburg, The Netherlands) instead of biotinylated goat anti-mouse IgG. Serum from (NZB x NZW)F1 mice was used as positive control for
Igh-1a allotype.
Transplantation . Author manuscript
Page /3 13
Total IgG and IgM antibody determination
Commercial ELISA kits (Bethyl Laboratories, Montgomery, TX) were used according to the manufacturer  recommendations.’
ELISA for IL-13 and IFN-  detectionγ
Commercial ELISA kits for mouse IL-13 and IFN-  (R&D Systems, Minneapolis, MN) were used according to the manufacturerγ ’
recommendations. Fifty-three serums were analyzed for IL-13 and IFN-  and IL-13/IFN-  ratio was calculated to appreciate type 1/type 2γ γ
polarization.
Pathological examination and immunohistochemical staining
All grafted mice involved in this study were prospectively followed for the development of clinical signs of GVHD according to the
scoring system initially proposed by Ferrara s group ( ). All mice developing clinical signs of GVHD and in particular abnormality in fur’ 15 
texture (severe ruffling) or in skin integrity (areas of denuded skin) were sacrificed and pathological examination of the skin, kidney, liver
and gastro-intestinal tract was performed. Healthy mice grafted the same day as mice developing GVHD-like lesions were randomly
selected and analyzed for chimerism and by a pathologist blinded to the nature of the mice being examined. Lesions were assessed on
paraffin-embedded tissues including skin, kidney, salivary gland, stomach and liver. Sections (5 m) were stained with either hematoxylinμ
eosin saffron (HES), periodic acid Schiff (PAS) or Masson s trichrome (MT) reagents. Immune complex deposition was detected on’
OCT-embedded snap-frozen kidney section after staining with either FITC-conjugated goat anti-mouse IgG, IgA, Kappa or Lambda light
chain Abs (Interchim, Montlu on, France) and UV fluorescence microscopy examination.ç
Statistical analysis
Statistical analysis was performed using SigmaStat 2.0 software (SPSS Inc., Jandel Scientific, Erkrath, Germany). Mann-Whitney
Rank Sum, Student or Fisher s exact tests as well as Pearson product moment correlation test were used as indicated. -Values <.05 weret ’ P 
considered as significant.
RESULTS
Mixed chimeric recipients exhibit higher levels of circulating IgG auto-antibodies after allogeneic BMT than full-donor- or
non-chimeric mice
In experimental conditions designed to limit donor engraftment, 284 BM recipients from 9 independent experiments were analyzed for
splenic engraftment 7 9 week post-BMT. Among these mice, 58.4  (166/284) had rejected their graft, whereas 9.9  (28/284) presented– % %
full-donor engraftment and 31.7  (90/284) were mixed chimeric mice with 5  to 98  of donor-derived cells. In most cases, engraftment% % %
level was found similar in the lymphoid and myeloid populations identified on their FSC/SSC profile (data not shown). Circulating
anti-dsDNA and AcL IgG auto-Ab titers were determined since they were frequently encountered in murine cGVHD ( ). At the16 
beginning of the study, both AcL and anti-dsDNA Ig auto-Ab titers were measured at the time of chimerism analysis. Since we observed a
good correlation between circulating anti-dsDNA and AcL IgG auto-Ab titers ( .0065, n 210; Pearson Product Moment Correlation, P = =
), either AcL or anti-dsDNA Ig auto-Ab titers were then determined in recipients. Higher levels of circulating IgG auto-AbsFigure 1A 
were found in mixed chimeric mice (anti-dsDNA auto-Abs: 192 U/mL 1-1716  (median range ), n 52 AcL auto-Abs: 834 U/mL 17-7466[ ] [ ] = [
, n 70) than in non-chimeric (anti-dsDNA Abs: 75 U/mL 2-825 , n 108, <.01; AcL Auto-Abs: 111 U/mL 10-4398 , n 117, <.01) or] = [ ] = P [ ] = P 
full-donor chimeric mice (anti-dsDNA Abs: 73 U/mL 2-266 , n 19, <.01; AcL auto-Abs: 164 U/mL 3-831 , n 24, <.01,[ ] = P [ ] = P 
Mann-Whitney Rank Sum Test). No statistical difference was observed between auto-Ab levels found in full-donor- or in non-chimeric
mice ( .91 for anti-dsDNA and .57 for AcL auto-Abs, Mann-Whitney Rank Sum Test). The high median auto-Ab levels observed inP = P =
mixed chimeric mice resulted from the presence of high levels (> to the mean  2 SD of Ab levels in naive mice) of auto-immune IgGs in+
nearly half of the mixed chimeric recipients (19/52 for anti-DNA and 31/70 for AcL auto-Abs) ( ). Such high levels of auto-AbFigure 1B 
IgG were seldom found in full-donor- (anti-DNA Abs: 0/19; AcL Abs: 5/24) or non-chimeric mice (anti-DNA Abs: 8/108; AcL Abs:
9/117) ( <.01 between mixed chimeric mice and other groups, except for AcL auto-Abs between mixed- and full-donor chimeric miceP 
where .07; Mann-Whitney Rank Sum Test, ).P = Figure 1B 
Self-immunization is preferentially observed in mixed chimeric recipients
An isotype switch from natural IgM auto-Abs that react weakly with self-antigens (Ags)  to high affinity pathogenic IgG is observed– –
during self-Ag immunization ( , ). Kinetics of IgM and IgG auto-Ab production after BMT were analyzed in 8 randomly selected17 18 
mice from each group (non-chimeric, full-donor and mixed chimeric mice). In a majority of mice (20/24), low levels of both anti-dsDNA
and AcL IgGs (< 151 U/mL) were detected, as observed in age-matched naive mice ( ). In these mice, natural IgM auto-AbFigure 1C 
serum concentration reached the levels found in age-matched naive mice 2 4 week post-BMT, therefore suggesting the absence of–
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immunization ( ). In contrast, a decrease of both anti-dsDNA and AcL auto-Ab IgM levels simultaneously to an increase ofFigure 1C 
auto-Ab IgG levels was observed in 4 mixed chimeric mice out of 8 analyzed ( ). This suggested a self-immunization in these 4Figure 1C 
mixed chimeric mice.
Mixed chimeric recipients exhibit higher levels of total circulating IgGs than full-donor- or non-chimeric mice
Total IgG Ab titers were measured 7 9 weeks post-BMT in the 3 different groups of recipients. Significant higher levels of total IgGs–
were detected in mixed chimeric mice (0.59 g/L 0.21 0.77  (median range ), n 10) than in non-chimeric (0. 30 g/L 0.09 0.72 ), n 6, μ [ – ] [ ] = μ [ – ] = P
<.05, Student test) or full-donor chimeric mice (0.23 g/L 0.07 1.05 ), n 10, <.05, Student test) ( ). No difference wast μ [ – ] = P t Figure 2A 
observed between non- and full-donor chimeric recipients ( .4, Mann-Whitney Rank Sum Test). Only mixed chimeric mice exhibitedP =
significant higher levels of total IgGs than naive BALB/c mice (0.11 g/L 0.07 0.12 , n 6, <.01, Student test). Altogether, increase ofμ [ – ] = P t 
circulating auto-IgG observed in mixed chimeric mice is associated with an increase of total IgGs, suggesting a polyclonal activation
related to the alloreactive conflict. This hypothesis is supported by the correlation existing between the levels of total IgGs and anti-DNA
IgG Abs (Correlation coefficient 0.566, <.01, n 26; Pearson Product Moment Correlation, ).= P = Figure 2B 
Chronic-GVHD-like lesions are preferentially observed in mixed chimeric mice and correlate with high levels of circulating
auto-Abs
Since auto-immunization may or may not result in autoimmune-like pathology ( ), recipients of each group (non-chimeric,19 
full-donor and mixed chimeric mice) were sacrificed 7 9 months post-BMT and examined for pathology. Chronic GVHD-like lesions (–
) were exclusively found in 13 out of 21 mixed chimeric recipients tested, whereas no lesions were observed in 13 full-donor-Figure 3A-B 
( <.01; Mann-Whitney Rank Sum Test) or 37 non-chimeric mice ( <.01, Mann-Whitney Rank Sum Test). Furthermore higher levels ofP P 
IgG auto-Abs (anti-dsDNA Abs: 25-1599 U/mL, median: 931; AcL Abs: 136-4078 U/mL, median: 779) were found in these 13 mixed
chimeric recipients developing cGVHD-like lesions when compared to healthy mixed chimeric mice ( <.01 for anti-dsDNA). ThisP 
strongly suggests a correlation between mixed chimeric state, high levels of IgG auto-Abs and cGVHD-like lesion occurrence.
Chronic GVHD-like lesions are preferentially found in mixed chimeric recipients demonstrating a divergent T and B chimerism
with mostly donor T cells and host B cells
To further explore cellular factors explaining the occurrence of cGVHD in mixed chimeric mice, we also analyzed the presence of
donor-derived cells in the thymus. Donor-derived cells in T lymphoid lineage were comparable in mixed chimeric mice developing or not
developing cGVHD-like lesions ( ). Reciprocal graft-host tolerance is linked to co-existence of thymic host and donor CD11c  DCTable 1 +
participating to the negative selection ( , ). However, engraftment in thymic DC was similar whatever the considered mixed chimeric5 20 
mice ( ). Because patients with cGVHD exhibited significantly higher plasmacytoid DC (pDC) numbers ( ), DC origin andTable 2 21 
subsets (myeloid vs. pDC) were also analyzed in the spleen of these mice. Based on B220 expression, myeloid DC (CD11c B220 ) can be+ −
distinguished from pDC (CD11c B220 ) ( , ). The repartition of splenic DC subsets or origin was also not different in mice+ + 22 23 
developing cGVHD-like lesions or not ( ).Table 2 
Host B-cell stimulation induced by alloreactive donor T cells is believed to induce and maintain cGVHD in a murine model involving
parental T cell transfer (without BM) into unirradiated F1 mice ( ). We therefore determined B-cell chimerism in the peripheral blood16 
and compared it to T-cell chimerism, 9 weeks post-BMT. Among 134 recipients from 4 independent experiments, 36 were mixed chimeric
mice ( ). Whereas similar B- and T-cell engraftment (in a given mouse) was found in 20 healthy mixed chimeric mice, the 16Table 1 
recipients developing cGVHD exhibited a divergent B- and T-cell chimerism with mostly host B cells (17.5  0 76  of donor CD19  B% [ – ] +
cells) and donor T cells (79  42 100  of donor CD3  T cells, ). This dissociated state of lymphoid chimerism was never observed% [ – ] + Table 1 
in full-donor chimeric mice since all the cells were from donor origin ( and ). Chimerism analysis in mixed chimeric miceFigure 4 Table 1 
was extended to T cell subsets. Comparable levels of donor chimerism were found in splenic CD4  T cells and in CD8  T cells from+ +
healthy mixed chimeric mice and mixed chimeric mice developing cGvHD-like lesions ( ). However, CD4/CD8 imbalance wasTable 1 
detected in mice developing such lesions while healthy recipients exhibited a CD4/CD8 ratio higher than 1 (P<.05, ).Table 1 
Type 1 (IFN- ) and 2 (IL-13) cytokine profiles were also determined in 53 grafted mice (11 healthy mixed chimeric mice, 10 mixedγ
chimeric mice developing cGVHD-like lesions, 23 non chimeric and 9 full donor chimeric mice). No significant differences were observed
between the IL-13/IFN-  ratio of healthy mixed chimeric mice (median 16.4; range: 1.7 368.5, 11) and that of mixed chimeric miceγ – n =
developing cGVHD-like lesions (median 12.7; range: 1.2 60, 10). Among these 53 mice tested, only one (a full donor chimeric mouse)– n =
exhibited an IL-13/IFN-  ratio lower than 1. Other grafted mice exhibited an elevated IL-13/IFN-gamma ratio. To confirm the origin ofγ
pathogenic auto-Abs presented in mixed chimeric recipients, allotype-specific ELISA were performed where auto-IgG were revealed by
allotype-specific anti-serum instead of non-specific goat anti-mouse IgGs. More than 85  of anti-dsDNA auto-Abs were from host%
BALB/c origin (median: 89.1  range: 48 98  of anti-dsDNA auto-IgG detected with non-allotype specific anti-IgG Abs were detected% [ – %]
with anti-1a allotype anti-serum; n 20). This demonstrates that persistence of host B cells is one potential factor involved in auto-Ab=
production.
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DISCUSSION
Several advantages have been reported to be associated with mixed chimerism state following RICT ( ). Among them, reciprocal5 –7 
graft-host tolerance appears prominent ( , , , ). Here, we show that about half of the mixed chimeric mice presented preferentially5 6 24 25 
higher levels of host-derived pathogenic IgG auto-Abs than full-donor or non-chimeric mice and that such mice developed subsequently
cGVHD-like lesions. Healthy mixed chimeric mice could be distinguished from those developing cGVHD-like lesions on the basis of B-
and T-cell chimerism. Indeed, mixed chimeric mice presenting cGVHD-like lesions exhibited a divergent B- and T-chimerism with mostly
host B cells and donor T cells while healthy chimeric mice showed similar engraftment in B and T cell populations. In addition, mixed
chimeric mice developing cGVHD-like lesions presented a CD4/CD8 imbalance. In this experimental model, we did not correlate the
occurrence of such cGVHD-like lesions with a particular distribution of DC subset or origin. Altogether, these results show that mixed
chimeric state is not always advantageous and suggest that such a state is not constantly associated with tolerance.
Chronic GVHD is an alloimmune disease associated with autoimmune features ( ) and is closely related to systemic autoimmune26 
disease in mice ( ). As such, cGVHD may result from the occurrence of multiple factors ( , ). Whereas some differences exists (for16 26 28 
an extensive review, see Ref. ), both human and mouse cGVHD share several features, including B-cell dysregulation ( , , ),28 16 26 28 
with a high prevalence of anti-nuclear auto-Abs ( , ) as well as clinical manifestations of autoimmune diseases ( , ), such as16 29 16 30 
scleroderma. In addition, certain ongoing clinical forms of human cGVHD can be treated by B-cell depletion ( ) as also described in31 –33 
murine model ( ) and in the treatment of some human autoimmune diseases ( ). A well-described murine model of cGVHD consisting16 34 
in administration of parental T cells to F1 mice showed that cGVHD occurrence resulting from auto-Ab mediated injury required host B
cell activation and Th2 cytokine secretion ( , ). In contrast, activation of donor CD8  CTL in the context of Th1 cytokine production16 35 +
eradicated self-reactive B cells rather leading to acute GVHD ( , , ). In this model, in contrast to the clinical situation, acute or16 35 36 
chronic GVHD occurs in the same delay after transplantation (depending on T cell polarization) and no BM was infused ( , , ).16 35 36 
Here, we used a different model in which fully major histocompatibility complex-mismatched BM containing approximately 2  T cells%
was administrated and cGVHD-like lesions appeared several months after allograft. We found a correlation between host B cell
persistence, elevated levels of auto-Abs (mostly from host origin) and of total circulating IgG as well as cGVHD occurrence, since only
mixed chimeric mice with dissociated donor T-cell and recipient B-cell chimerism develop cGVHD-like lesions. These observations fit
well with the parental T cell transfer into F1 mice model ( , , ). Increasing percentage of splenic activated CD4  T cells and16 35 36 +
increased levels of total IgGs, in addition to IgG auto-Abs, strongly suggest a polyclonal activation of host B cells due to alloreactive
conflict.
We could not correlate a cGVHD episode with a particular distribution of DC subset or origin. All mixed chimeric mice whatever their
status (healthy or none) exhibited host as well as donor splenic myeloid and pDC ( ). This suggests that such cells do not influenceTable 2 
cGVHD occurrence in our model. Nevertheless, autoreactive B cell activation may occur independently of DC in response to alloreactive
donor T cell stimulation ( ). Activated host B cells may be potent APC for indirect allorecognition ( ). This may contribute to16 37 
alloreactive donor T cell activation creating therefore an amplification loop.
There are some discrepancies with the studies reporting reciprocal host-graft tolerance in a murine model ( , ). There main24 25 
differences between this ( , ) and our model include: recipient strain (BALB/c mice in our study which are prone to autoimmune24 25 – –
disease and present an intrinsic type 2 cytokine bias, see Ref. , ), conditioning regimens (9.5 Gy lethal irradiation that ablate38 39 
completely the host immune system ( , ) vs. 6 Gy sublethal irradiation that transiently deplete circulating immune cells in our model)24 25 
and BM graft (co-administration of a mixture of 2x10 donor and recipient BM cells ( , ) vs. a restricted number of donor BM cells,7 24 25 
10 ). In these different 2 models, one can imagine that host B cell populations were totally different after BMT. Host immature B cells6 
derived from host BM (i.e., B-2 and B-1b cells, Ref. ) can be preferentially found in conditions associating lethal conditioning regimens40 
and rich donor plus host BM graft. In contrast, host mature B B-1a cells  or long-lived plasma cells that resist to -irradiation (i.e., RIC– – γ
regimens) ( , ) are observed after partial donor engraftment. The persistence of non dividing long-lived plasma despite41 42 
cyclophosphamide treatment is responsible from anti-dsDNA auto-Ab production in NZB/NZW lupus prone mice ( ), demonstrating the43 
role of these long-lived plasma cells in auto-Ab production. Preliminary results suggested an increased number of B-1a cells in mice
developing cGVHD-like lesion occurrence: 10-fold more splenic B-1a cells were found in mixed chimeric mice developing cGVHD than
healthy mixed chimeric, non-chimeric or full-donor chimeric mice. Together with the absence of donor B cells in such recipients
developing cGVHD-like lesions, excess of B-1a cells suggests that insufficient donor B cell engraftment can be implicated in the
development of such lesions. One may hypothesize that continuous activation of residual host mature B cells during the alloreactive
conflict results in increased auto-Ab production leading to autoimmune disease.
The hypothesis of altered immune reconstitution in mixed chimeric mice presenting cGVHD-like lesions is also sustained by absolute
count determination of circulating lymphocyte subsets. Mixed chimeric mice developing cGVHD exhibited severe lymphopenia 8 weeks
post-BMT when compared with healthy mixed chimeric mice (52 18 71  (median range  vs. 447 47 2686  CD19  cells/ l; 65 51 562[ – ] [ ] [ – ] + μ [ – ]
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vs. 837 284 2638  CD3  cells/ l, n 6 mice/group). In addition, these mice developing cGVHD showed evidence of a CD4/CD8[ – ] + μ =
imbalance. However, it was difficult to ascertain whether such altered immune reconstitution was due to GVHD or was responsible for
GVHD, as GVHD may lead to lymphopenia ( ).16 
The relation between mixed chimerism, persistence of host B cells and cGVHD after RICT in humans is presently difficult to assess.
Detailed clinical and chimerism data is scarce. In addition, several confounding factors such as the type of RIC regimen (i.e., with or
without anti-lymphocyte globulin, affecting B cells or not), the presence or absence of acute GVHD or the use of donor lymphocyte
infusions in the presence of mixed chimerism render data interpretation difficult. However, on the basis of a study involving 12 patients,
full donor B-cell chimerism was delayed when compared to full donor T-cell chimerism ( ). Moreover, although B cell chimerism was44 
not directly addressed, cGVHD occurrence in 2 patients with persisting mixed lymphoid chimerism was reported ( ). Although a study45 
involving a myeloablative conditioning regimen failed to find an association between circulating auto-Abs and cGVHD ( ), auto-Abs,46 
including lupus anticoagulant and AcL Abs, have been described in patients developing cGVHD ( , ). Finally, a recent interesting47 48 
clinical report shows that host-derived Abs persist much longer in the setting of RICT than after myeloablative allografts ( ). These49 
authors reported recently that this was due to the persistence of host plasma cells that resist to RIC regimen associating cyclophosphamide
and fludarabine ( ). In the 12 patients analyzed, host plasma cells detected in the bone marrow persisted whereas all T cells were from50 
donor origin. Disappearance of recipient plasma cells was correlated with decrease of anti-donor Ab titers ( ). Overall, our results50 
suggest that mixed chimerism after RICT could be associated with recipient B cell persistence, increased auto-immunity and cGVHD.
Such a novel association could be clinically highly relevant and could suggest that mixed chimerism is not always associated with
bi-directional tolerance. In addition, B-cell chimerism monitoring may contribute to cGVHD prevention by anticipating appropriate
immunosuppression.
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Abbreviations
 Ab : antibody
 AcL : anti-cardiolipin
 Ag : antigen
 APC : Antigen-presenting cell
 BM : bone marrow
 BMT : bone marrow transplantation
 cGVHD : chronic graft-versus-host disease
 DC : dendritic cell
 ds : double stranded
 FCS : fetal calf serum
 FSC : forward scatter
 GVHD : graft-versus-host disease
 GvL : graft-versus-leukemia
 HC : hematopoietic cell
 HES : hematoxylin eosin saffron
 IC : immune complexes
 mAb : monoclonal antibody
 MT : Masson s trichrome’
 OM : original magnification
 PAS : periodic acid Schiff
 PBS : phosphate buffer saline
 pDC : plasmacytoid dendritic cell
 PerCP : peridinin chlorophyll-a protein
 PE : phycoerythrin
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 RIC : reduced intensity conditioning
 RICT : reduced intensity conditioning transplantation
 SSC : side scatter
 TMB : 3,3 ,5,5 -tetramethylbenzidine′ ′
References:
 1 .  McSweeney PA , Niederwieser D , Shizuru JA . Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy
    with graft-versus-tumor effects . Blood . 2001 ; 97 : 3390 -
 2 .  Khouri IF , Saliba RM , Giralt SA . Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity,
    acute graft-versus-host disease, and treatment-related mortality . Blood . 2001 ; 98 : 3595 -
 3 .  Martino R , Caballero MD , Simon JA . Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity
    conditioning in acute myelogenous leukemia and myelodysplastic syndromes . Blood . 2002 ; 100 : 2243 -
 4 .     Mielcarek M , Martin PJ , Leisenring W . Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation . Blood . 2003 ; 102 
 : 756 -
 5 .      Sykes M . Mixed chimerism and transplant tolerance . Immunity . 2001 ; 14 : 417 -
 6 .     Ildstad ST , Sachs DH . Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts . Nature . 1984 ;
 307 : 168 -
 7 .  Mapara MY , Kim YM , Wang SP , Bronson R , Sachs DH , Sykes M . Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to
    fully allogeneic chimeras: a critical role for host antigen-presenting cells . Blood . 2002 ; 100 : 1903 -
 8 .  Fresnay S , Garnache-Ottou F , Plumas J , Seilles E , Tiberghien P , Saas P . Can tolerogenic dendritic cells help to modulate allo-immune responses in the setting of
    hematopoietic cell transplantation? . Transpl Immunol . 2003 ; 11 : 259 -
 9 .      Shlomchik WD , Couzens MS , Tang CB . Prevention of graft versus host disease by inactivation of host antigen-presenting cells . Science . 1999 ; 285 : 412 -
 10 .      Duffner UA , Maeda Y , Cooke KR . Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease . J Immunol . 2004 ; 172 : 7393 -
 11 .   Bittencourt MC , Perruche S , Contassot E . Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers .
   Blood . 2001 ; 98 : 224 -
 12 .  Perruche S , Kleinclauss F , Lienard A , Robinet E , Tiberghien P , Saas P . A single-platform approach using flow cytometry and microbeads to evaluate immune
    reconstitution in mice after bone marrow transplantation . J Immunol Methods . 2004 ; 294 : 53 -
 13 .  Perruche S , Kleinclauss F , Angonin R . A single intravenous infusion of apoptotic cells, an alternative cell-based therapy approach facilitating hematopoietic cell
    engraftment, did not induce autoimmunity . J Hematother Stem Cell Res . 2003 ; 12 : 451 -
 14 .     Cohen PL , Maldonado MA . Editor: Coligan JEKA , Margulies DH , Shevach EM , Strober W , Coico R . Animals models for SLE . Current Protocols in Immunology .
  New York, NY John Wiley & Sons Inc ; 1998 ; 15.20.7 -
 15 .  Cooke KR , Kobzik L , Martin TR . An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and
    endotoxin . Blood . 1996 ; 88 : 3230 -
 16 .   Hakim F , Fowler DH , Shearer GM , Gress RE . Editor: Coligan JEKA , Margulies DH , Shevach EM , Strober W , Coico R . Animal models of acute and chronic
    graft-versus-host disease . Current Protocols in Immunology . New York, NY John Wiley & Sons Inc ; 1998 ; 4.3.1 -
 17 .      Hahn BH . Antibodies to DNA . N Engl J Med . 1998 ; 338 : 1359 -
 18 .     Levine JS , Subang R , Koh JS , Rauch J . Induction of anti-phospholipid autoantibodies by beta2-glycoprotein I bound to apoptotic thymocytes . J Autoimmun . 1998 ; 11
 : 413 -
 19 .    Parry SL , Hall FC , Olson J , Kamradt T , Sonderstrup G . Autoreactivity versus autoaggression: a different perspective on human autoantigens . Curr Opin Immunol .
  1998 ; 10 : 663 -
 20 .  Brocker T , Riedinger M , Karjalainen K . Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce
    negative but not positive selection of thymocytes in vivo . J Exp Med . 1997 ; 185 : 541 -
 21 .    Clark FJ , Freeman L , Dzionek A . Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease . Transplantation .
  2003 ; 75 : 221 -
 22 .  Ferrero I , Held W , Wilson A , Tacchini-Cottier F , Radtke F , MacDonald HR . Mouse CD11c( ) B220( ) Gr1( ) plasmacytoid dendritic cells develop independently of+ + +
    the T-cell lineage . Blood . 2002 ; 100 : 2852 -
 23 .  Martin P , Del Hoyo GM , Anjuere F . Characterization of a new subpopulation of mouse CD8alpha  B220  dendritic cells endowed with type 1 interferon production+ +
    capacity and tolerogenic potential . Blood . 2002 ; 100 : 383 -
 24 .  Ildstad ST , Wren SM , Bluestone JA , Barbieri SA , Stephany D , Sachs DH . Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic
    repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10  B10. D2----B10) + . J Immunol . 1986 ; 136 : 28 -
 25 .  Sykes M , Eisenthal A , Sachs DH . Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population
    suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component . J Immunol . 1988 ; 140 : 2903 -
 26 .      Ferrara JL , Deeg HJ . Graft-versus-host disease . N Engl J Med . 1991 ; 324 : 667 -
 27 .      Kamradt T , Mitchison NA . Tolerance and autoimmunity . N Engl J Med . 2001 ; 344 : 655 -
 28 .      Lee SJ , Vogelsang G , Flowers ME . Chronic graft-versus-host disease . Biol Blood Marrow Transplant . 2003 ; 9 : 215 -
 29 .      Kier P , Penner E , Bakos S . Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies . Bone Marrow Transplant . 1990 ; 6 : 93 -
 30 .      Sullivan KM , Agura E , Anasetti C . Chronic graft-versus-host disease and other late complications of bone marrow transplantation . Semin Hematol . 1991 ; 28 : 250 -
 31 .   Ratanatharathorn V , Ayash L , Reynolds C . Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody . Biol Blood Marrow
   Transplant . 2003 ; 9 : 505 -
 32 .  Shimoni A , Hardan I , Avigdor A . Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive
    non-Hodgkin s lymphoma ’ . Br J Haematol . 2003 ; 122 : 457 -
 33 .  Canninga-van Dijk MR , van der Straaten HM , Fijnheer R , Sanders CJ , van den Tweel JG , Verdonck LF . Anti-CD20 monoclonal antibody treatment in 6 patients with
    therapy-refractory chronic graft-versus-host disease . Blood . 2004 ; 104 : 2603 -
 34 .      Martin F , Chan AC . Pathogenic roles of B cells in human autoimmunity; insights from the clinic . Immunity . 2004 ; 20 : 517 -
 35 .  Rus V , Svetic A , Nguyen P , Gause WC , Via CS . Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host
    disease. Regulatory role of donor CD8  T cells + . J Immunol . 1995 ; 155 : 2396 -
 36 .      Shustov A , Luzina I , Nguyen P . Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity . J Clin Invest . 2000 ; 106 : R39 -
 37 .  Schultz KR , Paquet J , Bader S , HayGlass KT . Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host
    disease . Bone Marrow Transplant . 1995 ; 16 : 289 -
 38 .  Hequet O , Vocanson M , Saint-Mezard P , Kaiserlian D , Nicolas JF , Berard F . CD4  T cells prevent skin autoimmunity during chronic autologous+
    graft-versus-host-disease . Am J Transplant . 2004 ; 4 : 872 -
 39 .   Bix M , Wang ZE , Thiel B , Schork NJ , Locksley RM . Genetic regulation of commitment to interleukin 4 production by a CD4( ) T cell-intrinsic mechanism + . J Exp
   Med . 1998 ; 188 : 2289 -
Transplantation . Author manuscript
Page /8 13
 40 .   Kantor AB , Stall AM , Adams S , Herzenberg LA , Herzenberg LA . Differential development of progenitor activity for three B-cell lineages . Proc Natl Acad Sci U S A .
  1992 ; 89 : 3320 -
 41 .      Hayakawa K , Asano M , Shinton SA . Positive selection of natural autoreactive B cells . Science . 1999 ; 285 : 113 -
 42 .      Manz RA , Arce S , Cassese G , Hauser AE , Hiepe F , Radbruch A . Humoral immunity and long-lived plasma cells . Curr Opin Immunol . 2002 ; 14 : 517 -
 43 .    Hoyer BF , Moser K , Hauser AE . Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice . J Exp Med . 2004 ;
 199 : 1577 -
 44 .  Childs R , Clave E , Contentin N . Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes
    alloimmune responses . Blood . 1999 ; 94 : 3234 -
 45 .   Peggs KS , Thomson K , Hart DP . Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses .
   Blood . 2004 ; 103 : 1548 -
 46 .   Rouquette-Gally AM , Boyeldieu D , Prost AC , Gluckman E . Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients .
   Transplantation . 1988 ; 46 : 238 -
 47 .  Sanmarco M , Vialettes B , Maraninchi D , Bernard D . Autoantibody formation after bone marrow transplantation: a comparison between autologous and allogeneic grafts
    . Autoimmunity . 1991 ; 11 : 712 -
 48 .      Quaranta S , Shulman H , Ahmed A . Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation . Clin Immunol . 1999 ; 91 : 106 -
 49 .  Bolan CD , Leitman SF , Griffith LM . Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic
    stem cell transplantation . Blood . 2001 ; 98 : 1687 -
 50 .  Griffith LM , McCoy JP Jr , Bolan CD . Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major
    ABO incompatible non-myeloablative haematopoietic cell transplantation . Br J Haematol . 2005 ; 128 : 668 -
Figure 1
Auto-immunity is preferentially observed in mixed chimeric mice
( ) A correlation between the levels of circulating anti-cardiolipin (AcL, x axis, Logarithmic representation) and anti-dsDNA (y axis,A 
Logarithmic representation) IgG auto-Abs assessed by ELISA was found in recipient mice 9 weeks post-BMT. The solid line represents the
calculated linear regression line of the observed data. Correlation coefficient 0.187, <.01, n 210 recipient mice (Pearson Product Moment= P =
Correlation). ( ) Circulating anti-dsDNA (black symbols - left hand side panel) and AcL (open symbols - right hand side panel) IgGB 
auto-Abs were significantly higher 9 weeks post-BMT in mixed chimeric mice (MCM, circles) than in non- (NCM, diamonds) or full-donor
chimeric mice (FDCM, triangles). White bars: mean for each group; doted line: mean of all groups; gray area: serum auto-Ab titers in 10
age-matched naive mice; : <.01 (Mann-Whitney Rank Sum Test). ( ) Kinetics of both IgG (open diamonds) and IgM (black diamonds)* P C 
AcL auto-Abs demonstrated a self-immunization in 4 out of 8 tested MCM, as attested by a simultaneous decrease of natural IgM auto-Abs
and an increase of pathogenic IgG auto-Abs. In contrast, low levels of pathogenic IgG auto-Abs and normal levels of natural IgM auto-Abs
(as compared to age-matched naive mice, range of AcL IgM auto-Ab titers: 2210.8 4358.3 U/ml) were observed in NCM (n 8) and FDCM (n– =
8). Error bars: SEM.=
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Figure 2
Significant higher levels of circulating total IgGs correlated with higher levels of IgG auto-Abs are preferentially found in mixed chimeric
mice
( ) Circulating total IgGs ( g/l) 9 weeks post-BMT were significantly higher in mixed chimeric mice (MCM; n 10) than in non- (NCM; nA μ = =
6) or in full-donor chimeric mice (FDCM; n 10). White bars: median for each group; doted line: median of all groups; grey area: median  2= +
SEM total IgGs found in 6 age-matched naive BALB/c mice; : <.01 (Mann-Whitney Rank Sum Test for NCM vs FDCM, otherwise* P 
Student test). ( ) Correlation between the levels of circulating total IgGs (x axis, 10 g/l) and anti-dsDNA (y axis, U/ml) IgG auto-Abt B 6 μ
assessed by ELISA in recipient mice 9 weeks post-BMT. The solid line represents the calculated linear regression line of the observed data.
Correlation coefficient 0.566, <.01, n 26 recipient mice (Pearson Product Moment Correlation).= P =
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Figure 3
Chronic GVHD-like lesions are detected in mixed chimeric recipient mice
( ) Mixed chimeric mice (8/10) developed glomerulonephritis as attested by renal mononuclear cell infiltrate (noted cGVHD, periodic acidA 
Schiff PAS  staining, original magnification OM  x80), a thickening of the glomerulus basal membrane due to IC deposition and a crescent[ ] [ ]
formation due to epithelial cell proliferation (noted cGVHD, Masson s trichrome MT  staining, OM x128). Glomerulus from a BM grafted’ [ ]
mouse non-developing cGVHD stained with PAS and MT (noted Ctrl) was shown as control. Immune complex deposition is identified by UV
fluorescent microscopy after labeling with either FITC-conjugated anti-kappa (right hand side immunofluorescence panel, OM x128) or
anti-lambda Abs (left hand side immunofluorescence panel, OM x128). ( ) Sclerodermatous cGVHD-like lesions in a mixed chimeric mouseB 
were attested by hair loss (upper panel) and skin structure alterations including fibrosis and mononuclear cell infiltrate (noted cGVHD, lower
panel, HES staining, OM x80). Skin section from a healthy BM grafted mouse was shown as control (noted Ctrl, HES staining, OM x80).
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Figure 4
Chronic GVHD is associated with the presence of host B cells and donor T cells
Recipient H-2 expression on CD3  T cells (middle column panel) and CD19  B cells (last column panel) was analyzed by flow cytometry ond + +
peripheral blood cells at time of sacrifice. Left hand side panels represented lymphoid chimerism obtained using an anti-recipient H-2 mAb
versus SSC gating. A representative flow cytometry profile from a mixed chimeric mouse among 16 mice developing cGVHD (MCM 1)#
shows B cells from recipient origin and T cells from donor origin. A representative flow cytometry profile from a healthy mixed chimeric
mouse out of 20 mice (MCM 2) shows similar proportions of T and B cells from both origins. Representative flow cytometry profiles for#
full-donor- (FDCM, n 34) and non-chimeric (NCM, n 64) mice are also shown.= =
Transplantation . Author manuscript
Page /13 13
TABLE 1
T and B cell subset and chimerism analysis
Chimeric state§ CD19+ CD3+ Spleen TCD4+ TCD8+ CD4/CD8 ratio Thymus thymocytes
NCM 0 0 5  (  64)[ – ] n = 0 0 7  (  67)[ – ] n = 1 0  7  (  21)[ – ] n = 0 0  3  (n  21)[ – ] = 2.3 1.4  3.2  (  21)[ – ] n = 1 0  5  (  25)[ – ] n =
MCM healthy 85 32  100  (  20)[ – ] n = 76 27  98  (  23)[ – ] n = 77 15  80  (  8)[ – ] n = 74.5 5  80  (  8)[ – ] n = 3.0 1 .2  5.3  (  8)[ – ] n = 63.5 10  90  (  12)[ – ] n =
MCM cGvHD 17.5 0  76 (  16)[ – ]  * n = 80 42  100  (  19)[ – ] n = 75 24  80  (  8)[ – ] n = 78.5 72  86  (  8)[ – ] n = 0.7 0.3  1.4 ( 8)[ – ]  * n = 61 7  87  (  7)[ – ] n =
FDCM 100 94  100  (  34)[ – ] n = 100 91  100  (  37)[ – ] n = 98 90  98  (  7)[ – ] n = 95 90  98  (  7)[ – ] n = 3.0 0.8  4.6  (  7)[ – ] n = 98 88  100  (  10)[ – ] n =
Results from 2 4 independent experiments are expressed as median range  of donor derived cells, except for CD4/CD8 ratio that represent the percentageof CD4 T cells divided by the percentage of– [ ]
CD8 T cells whatever their origin. Representative cytometric profiles for B and T chimerism were shown . Staining was performed on fresh cells, except in three mice per group for whichFigure 4 
CD3/CD4/CD8/H-2q staining was performed on frozen spleen cells. Chimericstate is defined by cytometry on lymphoid spleen cells; thymocytes represent double positive thymocytes as well as single
positive thymocytes.
 * The difference in the values between healthy MCM and cGVHD MCM groups is statistically significant (P < 0.05, Student t test).
NCM, nonchimeric mice; MCM, mixed chimeric mice; FDCM, full donor chimeric mice.
TABLE 2
Dendritic cell subset and chimerism analysis
Chimeric state§ mDC Spleen pDC mDC/pDC ratio Thymus DC (CD11c ) +
NCM
 22n = 1.5 0  4[ – ] 1 0  5[ – ] 3.3 0.8  18[ – ] 1 0  5[ – ]
MCM:
 healthy  10n = 74.5 5  99[ – ] 84 3  100[ – ] 2.2 1.2 21.3[ – ] 50 10  90[ – ]
 cGvHD  9n = 78 27  96[ – ] 86 15  97[ – ] 3.3 0.4  30[ – ] 47 20  84[ – ]
FDCM
 9n = 93 92  97[ – ] 98 92  100[ – ] 1.4 0.7  6.5[ – ] 100 95  100[ – ]
Results from 3 independent experiments are expressed as median range  of donor derived cells, except for mDC/pDC ratio, which represents the percentageof mDC divided by the percentage of pDC[ ]
whatever their origin. Dendritic cell gating was performed by cytometry as previously reported ( ). Chimeric stateis defined by cytometry on lymphoid spleen cells. No statistical difference was12 
observed between any groups. NCM: nonchimeric mice; MCM: mixed chimeric mice; FDCM: full donor chimeric mice; myeloid dendritic cells (mDC) were defined as CD11c B220 cells; +  −
plasmacytoid dendritic cells (pDC) were defined as CD11c B220 . +  +
